Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study

被引：1

作者：

Leotta, Salvatore ^{[1
]}

Duminuco, Andrea ^{[2
]}

Mule, Antonino ^{[3
]}

Tringali, Stefania ^{[3
]}

Mauro, Elisa ^{[1
]}

Vetro, Calogero ^{[1
]}

Maugeri, Cinzia ^{[1
]}

Parisi, Marina ^{[1
]}

Garibaldi, Bruno ^{[2
]}

Di Renzo, Nicola ^{[4
]}

Romano, Claudia ^{[4
]}

Pastore, Domenico ^{[5
]}

Gentile, Massimo ^{[6
]}

Vigna, Ernesto ^{[7
]}

Selleri, Carmine ^{[8
]}

Milone, Giuseppe ^{[1
]}

Markovic, Uros ^{[1
]}

机构：

[1] Azienda Osped Univ Policlin G Rodol San Marco, Hematol & BMT Unit, Catania, Italy

[2] Univ Catania, Hematol & BMT Unit, Dipartimento Special Med Chirurg, Catania, Italy

[3] Osped Riuniti Villa Sofia Cervello, Div Hematol & Bone Marrow Transplantat, Palermo, Italy

[4] Vito Fazzi Hosp, Lecce, Italy

[5] A Perrino Hosp, Hematol, Brindisi, Italy

[6] Hematol Unit AO Cosenza, Cosenza, Italy

[7] Azienda Osped Cosenza, Hematol Unit, Oncohematol Dept, Cosenza, Italy

[8] San Giovanni Dio & Ruggi Aragona Univ Hosp, Salerno, Italy

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-166546

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

618

引用

页码：11854 / 11855

页数：2

共 50 条

[1] Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study
Leotta, Salvatore
Markovic, Uros
Duminuco, Andrea
Mule, Antonino
Porretto, Ferdinando
Federico, Vincenzo
Gentile, Massimo
Pastore, Domenico
Nigro, Luca Lo
Selleri, Carmine
Serio, Bianca
Calafiore, Valeria
Patti, Caterina
Mauro, Elisa
Vetro, Calogero
Maugeri, Cinzia
Parisi, Marina
Fiumara, Paolo
Parrinello, Laura
Marino, Sara
Scuderi, Grazia
Garibaldi, Bruno
Musso, Maurizio
Renzo, Nicola Di
Vigna, Ernesto
Martino, Enrica Antonia
Raimondo, Francesco Di
Milone, Giuseppe
ANNALS OF HEMATOLOGY, 2024, 103 (09) : 3701 - 3712
[2] Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Goekbuget, Nicola
Dombret, Herve
Bonifacio, Massimiliano
Reichle, Albrecht
Graux, Carlos
Faul, Christoph
Diedrich, Helmut
Topp, Max S.
Brueggemann, Monika
Horst, Heinz-August
Havelange, Violaine
Stieglmaier, Julia
Wessels, Hendrik
Haddad, Vincent
Benjamin, Jonathan E.
Zugmaier, Gerhard
Nagorsen, Dirk
Bargou, Ralf C.
BLOOD, 2018, 131 (14) : 1522 - 1531
[3] Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
Goekbuget, Nicola
Zugmaier, Gerhard
Dombret, Herve
Stein, Anthony
Bonifacio, Massimiliano
Graux, Carlos
Faul, Christoph
Brueggemann, Monika
Taylor, Kate
Mergen, Noemi
Reichle, Albrecht
Horst, Heinz-August
Havelange, Violaine
Topp, Max S.
Bargou, Ralf C.
LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2665 - 2673
[4] Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab
Bargou, Ralf C.
Zugmaier, Gerhard
Bonifacio, Massimiliano
Graux, Carlos
Faul, Christoph
Topp, Max S.
Qui Tran
Zhang, Xinke
Goekbuget, Nicola
BLOOD, 2018, 132
[5] FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Jen, Emily Y.
Xu, Qing
Schetter, Aaron
Przepiorka, Donna
Shen, Yuan Li
Roscoe, Donna
Sridhara, Rajeshwari
Deisseroth, Albert
Philip, Reena
Farrell, Ann T.
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2019, 25 (02) : 473 - 477
[6] Blinatumomab in B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease: Initial Results of a Phase II Trial
Maiti, Abhishek
Kantarjian, Hagop M.
Short, Nicholas J.
Khouri, Maria
Takahashi, Koichi
Ohanian, Maro
Borthakur, Gautam
Konopleva, Marina
Daver, Naval
Estrov, Zeev
Alvarado, Yesid
Thompson, Philip A.
Jain, Nitin
Ravandi, Farhad
Garcia-Manero, Guillermo
Cholick, Carissa N.
Khouri, Rita
O'Brien, Susan M.
Jabbour, Elias J.
BLOOD, 2017, 130
[7] Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia (vol 131, pg 1522, 2018)
Gokbuget, N.
Dombret, H.
Bonifacio, M.
BLOOD, 2019, 133 (24) : 2625 - 2625
[8] A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
Haddad, Fadi
Kantarjian, Hagop
Short, Nicholas J.
Konopleva, Marina
Jain, Nitin
Ravandi, Farhad
Daver, Naval
Alvarado, Yesid
Takahashi, Koichi
Garcia-Manero, Guillermo
Velasquez, Michelle
Garris, Rebecca
Jabbour, Elias J.
BLOOD, 2021, 138
[9] THE MRDITALLAB PROJECT: BRINGING MINIMAL RESIDUAL DISEASE INTO REAL-LIFE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
Chiaretti, S.
Della Starza, I.
Santoro, A.
Spinelli, O.
Elia, L.
Cucci, R.
Vignetti, M.
Fabbiano, F.
Bassan, R.
Rambaldi, A.
Foa, R.
HAEMATOLOGICA, 2019, 104 : 94 - 94
[10] Differential Impact of Minimal Residual Disease Negativity According to the Salvage Status in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Jabbour, Elias
Short, Nicholas J.
Jorgensen, Jeffrey L.
Yilmaz, Musa
Ravandi, Farhad
Wang, Sa A.
Thomas, Deborah A.
Khoury, Joseph
Champlin, Richard E.
Khouri, Issa
Kebriaei, Partow
O'Brien, Susan M.
Garcia-Manero, Guillermo
Cortes, Jorge E.
Sasaki, Koji
Dinardo, Courtney D.
Kadia, Tapan M.
Jain, Nitin
Konopleva, Marina
Garris, Rebecca
Kantarjian, Hagop M.
CANCER, 2017, 123 (02) : 294 - 302

← 1 2 3 4 5 →